FOURNEL ADVISORY SUPPORTS A FRENCH BIOTECH COMPANY IN ITS FUNDRAISING TO MARKET AND COMMERCIALISE ITS TECHNOLOGY.
Founded in 2016 by Jean-François CHATAL, a pioneer in nuclear medicine, NAOGEN PHARMA develops, produces and markets innovative radiopharmaceutical products for non-invasive molecular imaging (PET – Positron Emission Tomography) for hospital nuclear medicine departments.
FOURNEL ADVISORY assisted NAOGEN PHARMA in raising funds from private and institutional investors in order to obtain marketing authorization for its products by 2022.